SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...

Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

In addition to Evercore ISI, Moderna also received a Hold from Needham’s Joseph Stringer in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Sell rating on Moderna (NASDAQ ...

The quarterly earnings season has seen roughly 86% of firms reported results that have topped analysts’ estimates. S&P 500 earnings growth for the period is seen rising 9.3% versus a year ago, on ...

NEW YORK, NY / ACCESS Newswire / October 22, 2025 / Every investor knows the reflex. You see the words reverse split, and your instincts flinch. It’s practically Pavlovian. But sometimes, what looks ...

NEW YORK, NY / ACCESS Newswire / October 23, 2025 / There are two kinds of tightening in business. The kind you do because you have to, and the kind you do because you’re getting ready to move faster.

Today’s ACT Brief explores how eConsent is modernizing participant engagement, highlights new data on global representation in breast cancer trials, and examines Moderna’s decision to halt its Phase ...

A bipartisan group of senators is working to draft legislation to reform a fast-growing hospital drug discount program designed to help low-income patients.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

In addition to Needham, Moderna also received a Hold from TR | OpenAI – 4o’s Dex Genotek in a report issued today. However, on October 17, Wolfe Research maintained a Sell rating on Moderna (NASDAQ: ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

Moderna said its cytomegalovirus (CMV) vaccine candidate, mRNA-1647, failed to meet the outcomes of preventing CMV infections in seronegative women of childbearing age in a phase ...